Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Howson

Interventional Pain Medicine Green Bay, WI Medical Doctor

NPI 1508129826 CMS profile 1384291

2845 Greenbrier Rd, Green Bay, WI 54311

Open in the dashboard

General payments

$114,152

359 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$345 paid to institutions, not to them · program year 2023

Through program year 2025, Christopher Howson of Green Bay, WI is reported in the CMS Open Payments database as having received $114,152 across 359 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $345 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,311 74
2024 General $15,210 52
2023 General $15,414 45
2022 General $22,442 83
2021 General $20,652 50
2020 General $6,518 31
2019 General $606 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Howson
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Christopher Howson were reported at $33,311. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Christopher Howson Interventional Pain Medicine median Middle half National median
2019 $606 $684 $216–$2,079 $163
2020 $6,518 $382 $122–$1,109 $114
2021 $20,652 $552 $167–$1,554 $132
2022 $22,442 $605 $187–$1,924 $149
2023 $15,414 $671 $195–$1,915 $160
2024 $15,210 $684 $206–$1,837 $164
2025 $33,311 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $60,291 122 payments
  2. Medtronic, Inc. $38,662 84 payments
  3. Abbott Laboratories $9,506 43 payments
  4. Medtronic USA, Inc. $2,241 18 payments
  5. Relievant Medsystems, Inc. $1,220 15 payments
  6. SPR Therapeutics, Inc $441 7 payments
  7. AbbVie, Inc. $248 10 payments
  8. Nevro Corp. $207 4 payments
  9. Spinal Simplicity, LLC $161 2 payments
  10. Allergan Inc. $139 8 payments
  11. Other $1,036 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $80,605 50 payments
  2. Travel and Lodging $15,936 76 payments
  3. Food and Beverage $10,661 228 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $5,350 3 payments
  5. Consulting Fee $1,600 2 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $32,586 58 payments
  2. WaveWriter Alpha Prime 16 $13,043 37 payments
  3. WAVEWRITER ALPHA $10,180 6 payments
  4. General - Therapies $8,124 11 payments
  5. PROCLAIM $7,614 15 payments
  6. Intracept $5,625 3 payments
  7. GENERAL PAIN MANAGEMENT $3,897 17 payments
  8. RESTORE $3,682 5 payments
  9. INTELLIS $2,026 12 payments
  10. GENERAL - PAIN MANAGEMENT $2,000 3 payments
  11. Other $12,907 203 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,102

Median for Pain Management: 951

Drug cost

$57,164

Median for Pain Management: $26,034

Branded share of claims

21.5%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 13 $10,405
Gabapentin Generic 376 $6,874
Buprenorphine Generic 35 $6,647
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 302 $5,595
Xtampza Er Oxycodone Myristate Brand 13 $5,473
Pregabalin Generic 199 $4,673
Celecoxib Generic 123 $3,529
Duloxetine Hcl Generic 197 $2,865
Oxcarbazepine Generic 54 $2,024
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 103 $1,864

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$135,784

Of which drugs: $19,719

Medicare patients

365

Average age 71

Services billed

4,143

212 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 38%
Diabetes 30%
Ischemic heart disease 29%
Chronic kidney disease 27%
Heart failure 18%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 52 291 $204

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $51
$51 — —
Qutenza
  • Averitas Pharma Inc. $40
$40 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

359 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record